Catalyst Capital puts Therapure contract development unit up for sale: Blooomberg

Catalyst Capital Group is exploring options for Therapure Biopharma, Bloomberg reported. Catalyst has hired Wells Fargo & Co to find a buyer for the contract development and manufacturing part of its business, the story said. The Therapure unit could fetch C$400 million ($302 million), Bloomberg said. Catalyst is also interviewing banks to advise on an IPO for Therapure’s proprietary products division, Bloomberg said.